Gilead Sciences, Inc. (NASDAQ:GILD) Shares Bought by Ranch Capital Advisors Inc.

Ranch Capital Advisors Inc. increased its stake in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 57.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 19,555 shares of the biopharmaceutical company's stock after purchasing an additional 7,153 shares during the quarter. Ranch Capital Advisors Inc.'s holdings in Gilead Sciences were worth $1,806,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the company. HHM Wealth Advisors LLC raised its stake in shares of Gilead Sciences by 118.5% in the fourth quarter. HHM Wealth Advisors LLC now owns 284 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 154 shares during the period. YANKCOM Partnership bought a new stake in Gilead Sciences in the 4th quarter valued at about $28,000. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences during the fourth quarter valued at about $29,000. Crews Bank & Trust bought a new position in Gilead Sciences during the fourth quarter worth about $31,000. Finally, Stephens Consulting LLC increased its stake in shares of Gilead Sciences by 325.0% in the fourth quarter. Stephens Consulting LLC now owns 340 shares of the biopharmaceutical company's stock worth $31,000 after purchasing an additional 260 shares in the last quarter. Hedge funds and other institutional investors own 83.67% of the company's stock.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on GILD shares. Daiwa America upgraded Gilead Sciences to a "hold" rating in a research report on Monday, November 18th. Oppenheimer raised their target price on Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 4th. Citigroup started coverage on Gilead Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $125.00 price target on the stock. Mizuho increased their price target on shares of Gilead Sciences from $90.00 to $100.00 and gave the stock an "outperform" rating in a report on Thursday, November 21st. Finally, BMO Capital Markets boosted their price objective on shares of Gilead Sciences from $110.00 to $115.00 and gave the company an "outperform" rating in a research note on Wednesday, February 12th. Eleven analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and four have given a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $104.52.

Remove Ads

Insider Activity

In other news, CFO Andrew D. Dickinson sold 8,500 shares of the firm's stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $91.96, for a total value of $781,660.00. Following the sale, the chief financial officer now directly owns 132,373 shares in the company, valued at approximately $12,173,021.08. This trade represents a 6.03 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last three months, insiders have sold 293,356 shares of company stock worth $29,166,240. 0.16% of the stock is currently owned by company insiders.

Gilead Sciences Trading Down 1.8 %

Shares of NASDAQ GILD traded down $2.09 during midday trading on Tuesday, hitting $115.12. The company's stock had a trading volume of 7,647,636 shares, compared to its average volume of 8,160,293. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a market cap of $143.37 billion, a P/E ratio of 311.18, a price-to-earnings-growth ratio of 0.71 and a beta of 0.21. The business's 50 day moving average is $100.12 and its two-hundred day moving average is $91.91.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share for the quarter, topping the consensus estimate of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. As a group, equities research analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a dividend of $0.79 per share. This represents a $3.16 annualized dividend and a yield of 2.74%. The ex-dividend date is Friday, March 14th. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio (DPR) is 854.05%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.